Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Epigral Ltd ( (IN:EPIGRAL) ) has shared an update.
Epigral Limited reported Q3 FY26 revenue of ₹603 crore, down from ₹649 crore a year earlier, with profit after tax falling to ₹39 crore from ₹104 crore as margins were hit by softer realizations, higher raw material costs and inventory effects. EBITDA margin declined to 17% from 23% sequentially, and for the nine months of FY26 revenue slipped 7% to ₹1,807 crore, EBITDA margin narrowed to 22% from 28%, and plant utilization eased to 76% amid subdued demand linked to an extended monsoon and plant maintenance, even as net debt rose modestly to ₹557 crore and leverage remained contained at 1.0x Net Debt/EBITDA. Management highlighted that demand has strengthened since mid-November and expects margin improvement from Q4 FY26, while underscoring that capex of ₹337 crore in the first nine months and on-schedule projects in CPVC, epichlorohydrin and a wind-solar hybrid power plant are poised to drive scalable, profitable growth and enhance integration from FY27 onward, supporting the company’s long-term value-creation agenda for stakeholders.
More about Epigral Ltd
Epigral Limited is one of India’s leading integrated chemical manufacturers, with a significant share of its revenue coming from derivatives and specialty chemical businesses. The company operates large-scale plants with utilization levels in the mid-to-high 70% range and is actively expanding capacity in CPVC, epichlorohydrin and renewable power to strengthen integration and support future growth.
Average Trading Volume: 2,927
Technical Sentiment Signal: Sell
Current Market Cap: 45.11B INR
See more data about EPIGRAL stock on TipRanks’ Stock Analysis page.